TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38116137
Drug: Isotoxic dose
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotoxic dose escalation to 75 Gy in 30 fractions with concurrent bevacizumab (BEV)
Study: 38116642
Drug: Daratumumab (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab (16 mg/kg) administered intravenously 16 times over 6 months
Study: 38117500
Drug: Daily-delivered meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily-delivered meals
Study: 38117526
Drug: PF-07038124, 0.01%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07038124, 0.01%, topical ointment once daily for 6 weeks
Study: 38117526
Drug: Vehicle, topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle, topical ointment once daily for 6 weeks
Study: 38117527
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam 3.75 mg
Study: 38118022
Drug: Doxycycline PEP
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline PEP (200 mg taken within 72 hours after condomless sex)
Study: 38118249
Drug: PRT543 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT543 35 mg
Study: 38118249
Drug: PRT543 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT543 45 mg
Study: 38118406
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CART-BCMA and CART-19
Study: 38123789
Drug: Radium-223 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 + Endocrine Therapy (ET)
Study: 38833643
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Endocrine Therapy (ET)
Study: 38124098
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) iron treatment during early pregnancy
Study: 38124098
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron treatment during early pregnancy
Study: 38124112
Drug: Brazikumab (210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazikumab (210 mg) administered subcutaneously every 4 weeks for 100 weeks
Study: 38124481
Drug: ONC201 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONC201 and paxalisib combination treatment
Study: 38124508
Drug: Oral swabs
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral swabs collected from participants with early syphilis
Study: 38124508
Drug: Oral shedding
Normalized name: Peroxy Shield Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral shedding in participants aged 18-29 years
Study: 38124528
Drug: Rasagiline 1
Normalized name: rasagiline 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasagiline 1 mg orally once daily
Study: 38124551
Drug: Adjunctive perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjunctive perampanel (mean daily dose of 4 mg/day)
Study: 38125301
Drug: Thyroid-stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid-stimulating hormone (TSH) levels
Study: 38125672
Drug: Single-spin PRP
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-spin PRP preparation (3,000rpm for 15 minutes)
Study: 38125672
Drug: Double-spin PRP
Normalized name: HEMOPHILUS B PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-spin PRP preparation (first spinning at 1,500rpm for 6 minutes, continuing at 2,500rpm for 15 minutes)
Study: 38125722
Drug: LTX-315 and
Normalized name: LTX-315
DrugBank: LTX-315 (DB12748)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LTX-315 and adoptive T-cell therapy
Study: 38126083
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluoxetine, placebo, and cognitive behaviour therapy
Study: 38126183
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate treatment
Study: 38126709
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone 192 mg
Study: 38126709
Drug: Extended-release naltrexone
Normalized name: bupropion / naltrexone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naltrexone 384 mg
Study: 38126709
Drug: NTX levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NTX levels < 2 ng/mL
Study: 38126764
Drug: Sapanisertib 3
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib 3 or 4 mg daily together with metformin once to three times daily (500-1,500 mg).
Study: 38127015
Drug: Inorganic nitrite
Normalized name: Nitrite
DrugBank: Nitrite (DB12529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inorganic nitrite 40 mg 3 times daily
Study: 38127212
Drug: Cytoreductive surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Study: 38127508
Drug: FATIGUEWALK (FaW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FATIGUEWALK (FaW) plus treatment as usual (TAU)
Study: 38127586
Drug: Emicizumab 3
Normalized name: Emicizumab 30 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab 3 mg/kg maintenance dose every 2 weeks for 52 weeks
Study: 38128008
Drug: Blood specimens
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood specimens for SARS-CoV-2 antibody testing
Study: 38128401
Drug: Caregiver emotional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver emotional reactions at mid-treatment
Study: 38128401
Drug: Child PTS
Normalized name: Senna-Relief Childs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Child PTS at mid-treatment
Study: 38128402
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of behavioral activation and mindfulness
Study: 38128414
Drug: PepGNP-Dengue (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: PepGNP-Dengue (low dose)
Study: 38128414
Drug: PepGNP-Dengue (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: PepGNP-Dengue (high dose)
Study: 38128414
Drug: Vehicle-GNP (low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle-GNP (low dose)
Study: 38128414
Drug: Vehicle-GNP (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle-GNP (high dose)
Study: 38128414
Drug: PepGNP-Dengue (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: PepGNP-Dengue (both doses)
Study: 38128460
Drug: Erythropoietin (EPO;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO; 40,000 IU/ml)
Study: 38128724
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (specific antibiotics not detailed)
Study: 38129525
Drug: Berzosertib with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berzosertib with radiotherapy (RT) at six dose levels (highest dose 240 mg/m)
Study: 38129731
Drug: Warmed IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed IgG 20% 0.4 g/kg
Study: 38129731
Drug: Warmed IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warmed IgG 20% 1.0 g/kg
Study: 38129731
Drug: Unwarmed IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unwarmed IgG 20% 1.0 g/kg
Study: 38129910
Drug: Real sensorimotor
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real sensorimotor transcranial stimulation (PAS) with robot-assisted therapy
Study: 38129910
Drug: Sham sensorimotor
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham sensorimotor transcranial stimulation (PAS) with robot-assisted therapy
Study: 38130041
Drug: Ozanimod 0.92
Normalized name: ozanimod 0.92 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 0.92 mg with SSRI/SNRI
Study: 38130041
Drug: Ozanimod 0.92
Normalized name: ozanimod 0.92 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 0.92 mg without SSRI/SNRI
Study: 38130375
Drug: Duloxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine plus exercise (supervised treadmill walking 3 times weekly, duloxetine starting at 30 mg daily titrating to 60 mg daily)
Study: 38130409
Drug: Zoliflodacin plus
Normalized name: Zoliflodacin
DrugBank: Zoliflodacin (DB12817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoliflodacin plus doxycycline combination therapy
Study: 38130645
Drug: QL0911 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL0911 (1 μg/kg subcutaneously once weekly for 24 weeks, adjusted to maintain platelet counts from 50 × 10^9/L to 200 × 10^9/L)
Study: 38130645
Drug: Placebo (subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneously once weekly for 24 weeks)
Study: 38131181
Drug: Exposure-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure-based cognitive behavior therapy (Exp-CBT)
Study: 38131181
Drug: Traditional cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional cognitive behavior therapy (T-CBT)
Study: 38131294
Drug: Neoadjuvant stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant stereotactic body radiotherapy (SBRT) plus adebrelimab and chemotherapy
Study: 38131617
Drug: Tofacitinib maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib maintenance therapy
Study: 38131621
Drug: famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: famciclovir 500 mg twice daily for 12 weeks
Study: 38131621
Drug: natalizumab treatment
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: natalizumab treatment (before famciclovir)
Study: 38131628
Drug: Neoadjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant therapy (including systemic therapy or chemoradiation)
Study: 38133554
Drug: Oral selgantolimod
Normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selgantolimod 1.5 mg once weekly for 24 weeks
Study: 38133554
Drug: Oral selgantolimod
Normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selgantolimod (3 mg or 1.5 mg)
Study: 38133554
Drug: Oral selgantolimod
Normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral selgantolimod (up to 3 mg)
Study: 38133601
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAA) related HCV cure
Study: 38133639
Drug: RSVPreF3 60
Normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVPreF3 60 µg coadministered with dTpa
Study: 38133639
Drug: RSVPreF3 120
Normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVPreF3 120 µg coadministered with dTpa
Study: 38133639
Drug: RSVPreF3 120
Normalized name: RSVPreF3 OA
DrugBank: Respiratory syncytial virus vaccine, adjuvanted (DB17762)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVPreF3 120 µg (second vaccination)
Study: 38133639
Drug: RSVPreF3 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSVPreF3 (both doses)
Study: 38133825
Drug: Malnutrition diagnosed
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Malnutrition diagnosed using GLIM criteria at 7 weeks after treatment initiation
Study: 38133914
Drug: Once-daily sublingual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily sublingual 17-β estradiol
Study: 38133914
Drug: Twice-daily sublingual
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily sublingual 17-β estradiol
Study: 38133914
Drug: Transdermal 17-β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17-β estradiol
Study: 38133914
Drug: Lipid panel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid panel, homeostatic model assessment for insulin resistance, coagulation factors II, IX, and XI, Von Willebrand factor, activated protein C resistance, protein C, and protein S
Study: 38134037
Drug: automated directly
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: automated directly observed therapy-conditional economic incentive (aDOT-CEI) intervention
Study: 38134305
Drug: Monitoring trachoma
Normalized name: Chlamydia trachomatis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring trachoma transmission with antibody data; estimated median IgG half-life of 3 years; seroreversion rate of 2.5 per 100 person-years (95% CI, 1.6-3.5)
Study: 38134484
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block with 100 mg of ropivacaine
Study: 38134484
Drug: Sciatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sciatic nerve block with 100 mg of ropivacaine
Study: 38134948
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus cisplatin-based chemotherapy
Study: 38134948
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus cisplatin-based chemotherapy
Study: 38135184
Drug: nab-paclitaxel +
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel + cisplatin + capecitabine as induction chemotherapy for three cycles
Study: 38135187
Drug: SMART (Stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART (Stereotactic MR-guided adaptive radiation therapy) delivered on a 0.35 T MR-guided system prescribed to 50 Gy in 5 fractions
Study: 38135187
Drug: SMART (Stereotactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART (Stereotactic MR-guided adaptive radiation therapy)
Study: 38135320
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day of dark chocolate containing 500 mg total polyphenols and 100 mg vitamin E (n=25)
Study: 38135371
Drug: Oral decitabine-cedazuridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral decitabine-cedazuridine (35 mg decitabine and 100 mg cedazuridine once daily for 5 days)
Study: 38135371
Drug: Intravenous decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous decitabine (20 mg/m2)
Study: 38135371
Drug: Oral decitabine-cedazuridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral decitabine-cedazuridine
Study: 38135485
Drug: Pudexacianinium (ASP5354)
Normalized name: Pudexacianinium
DrugBank: Pudexacianinium (DB19161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudexacianinium (ASP5354) 1.0 mg intravenous injection
Study: 38135485
Drug: Pudexacianinium (ASP5354)
Normalized name: Pudexacianinium
DrugBank: Pudexacianinium (DB19161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudexacianinium (ASP5354) 3.0 mg intravenous injection
Study: 38135485
Drug: Pudexacianinium (ASP5354)
Normalized name: Pudexacianinium
DrugBank: Pudexacianinium (DB19161)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pudexacianinium (ASP5354) 0.3 mg intravenous injection
Study: 38135494
Drug: Early and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early and exclusive enteral nutrition (60-80 mL/kg/day within the first 36 hours after birth)
Study: 38137533
Drug: Guideline-oriented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-oriented therapy
Study: 38140005
Drug: Ped-TMZ oral
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ped-TMZ oral suspension
Study: 38140005
Drug: TMZ capsules
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: TMZ capsules
Study: 38140184
Drug: Baseline IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline IgG levels ≥ 1.3 µg/mL
Study: 38140184
Drug: Baseline IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline IgG levels < 1.3 µg/mL
Study: 38141138
Drug: Iodine-containing multivitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-containing multivitamin and mineral supplements (≥ 150 μg/day)
Study: 38141138
Drug: Non-users of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-users of iodine-containing supplements
Study: 38141879
Drug: Incidental axillary
Normalized name: Iva axillaris pollen
DrugBank: Iva axillaris pollen (DB10764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incidental axillary radiation therapy (RT) dose at axilla level I
Study: 38142044
Drug: Sildenafil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (2 mg/kg/dose enterally every 12 hours for 7 days, 14 doses)
Study: 38142046
Drug: Family-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Based Treatment with Intensive Parental Coaching (IPC)
Study: 38142448
Drug: Elevated white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated white blood cell (WBC) count >11 × 10^9/L
Study: 38142448
Drug: WBC count
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: WBC count >12 × 10^9/L (when hematocrit controlled at ≤45%)
Study: 38142695
Drug: Leterovir (480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leterovir (480 mg once daily, adjusted to 240 mg for participants on cyclosporin A) for 200 days
Study: 38142697
Drug: Standard optimal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard optimal treatment alone (Control)
Study: 38142892
Drug: IV ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV ketamine infusions (3 infusions over 11 days)
Study: 38144428
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein supplementation (60 g)
Study: 38144428
Drug: Moderate protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate protein supplementation (20 g)
Study: 38145113
Drug: PyroHC (pyrotinib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PyroHC (pyrotinib, trastuzumab, and chemotherapy)
Study: 38145113
Drug: PyroHC (first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: PyroHC (first-line treatment)
Study: 39514895
Drug: Computer-based training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-based training for cognitive behavioral therapy (CBT4CBT)
Study: 38145231
Drug: Multimodal AI
Normalized name: AI-128
DrugBank: AI-128 (DB05841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal AI system using ChatGPT and anterior segment images, smartphone-based, aiming for ≥90% sensitivity and ≥95% specificity for diagnosing and triaging ophthalmic diseases.
Study: 38145714
Drug: High dietary
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dietary fiber (HFib) intervention with daily snacks high in dietary fiber (10-12 g/day) for 18 weeks.
Study: 38146256
Drug: Oral anti-coagulants
Normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-coagulants (OAC)
Study: 38146256
Drug: In-hospital rhythm
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital rhythm control strategies (anti-arrhythmic drug use)
Study: 38146908
Drug: Aspirin continuation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin continuation within 5 days before surgery (n=269)
Study: 38146908
Drug: Non-aspirin group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-aspirin group (stopped aspirin no later than 5 days before surgery) (n=205)
Study: 38147137
Drug: Isatuximab 10
Normalized name: ISATUXIMAB 100 mg in 5 mL INTRAVENOUS INJECTION, SOLUTION, CONCENTRATE [Sarclisa]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isatuximab 10 mg/kg weekly for 4 weeks then every 2 weeks for 8 weeks
Study: 38147180
Drug: Surgical reconstructive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical reconstructive therapy with adjunctive use of Er:YAG laser
Study: 38147180
Drug: Surgical reconstructive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical reconstructive therapy without adjunctive use of Er:YAG laser (control group)
Study: 38147180
Drug: Surgical reconstructive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical reconstructive therapy
Study: 38147268
Drug: Non-invasive pulsed
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive pulsed radiofrequency (NipRF) therapy applied to the greater occipital nerve (GON)
Study: 38147281
Drug: Iron-whey-protein microspheres
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-whey-protein microspheres (14 mg daily, 25 mg daily, 50 mg daily) for 12 weeks
Study: 38147281
Drug: Prior oral
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior oral iron product
Study: 38147326
Drug: Intensive food-as-medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive food-as-medicine program (providing healthy groceries for 10 meals per week, dietitian consultations, nurse evaluations, health coaching, and diabetes education for 1 year)
Study: 38147326
Drug: Intensive food-as-medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive food-as-medicine program
Study: 38147525
Drug: GLPG3312 (Pan-SIK
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG3312 (Pan-SIK Inhibitor)
Study: 38147816
Drug: Trastuzumab biosimilar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab biosimilar (HLX02), pertuzumab, and chemotherapy
Study: 38148064
Drug: Vasopressin 0.2
Normalized name: VASOPRESSIN 0.2 UNIT/ML/NACL INJ,100ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin 0.2 IU/ml
Study: 38148064
Drug: Vasopressin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin 0.1 IU/ml
Study: 38148064
Drug: Vasopressin 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin 0.05 IU/ml
Study: 38148327
Drug: SCT200 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCT200 monotherapy (from previous phase I study)
Study: 38148411
Drug: Other chemotherapy
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other chemotherapy regimens
Study: 38148468
Drug: Inhaled iloprost
Normalized name: iloprost Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled iloprost (20 μg) for 15 minutes after internal mammary artery harvesting